Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Vaccine against Chlamydia not far away

16.11.2009
When a woman becomes infected with Chlamydia, the first white blood cells that arrive at the scene to fight the infection are not the most effective. This is shown by a thesis from the Sahlgrenska Academy.

This discovery could pave the way for the relatively rapid development of a vaccine against Chlamydia.

"Now that we know how the body defends itself against the Chlamydia bacteria, we can develop a vaccine that optimises that defence. We have a basic understanding of how the vaccine could work, but some work remains to be done. We believe that it will take a few years before the vaccine becomes a reality," says researcher Ellen Marks, the author of the thesis.

The body defends itself against infections with a type of white cell called the T lymphocyte. When these blood cells take on the bacteria, they trigger an inflammation that can damage tissue, so there are also other similar blood cells whose main task is to reduce the inflammation and protect tissue. Ellen Marks and her colleagues are the first research team to discover that these anti-inflammatory forces predominate in the lower parts of the female genital tract, mainly mediated by a hormone called IL-10, which is highly protective against tissue damage.

"The result is that the T lymphocytes that could fight Chlamydia are not concentrated in the lower vagina, and the infection can move up towards the womb and fallopian tubes relatively unhindered," says Ellen Marks.

The research team already has a concept of how a vaccine based on this new understanding could work, and they have also tested it on mice.

"The method of administration is an important remaining issue. Previous research has shown that injections don't work, and so the vaccine will probably need to be given either as a nasal spray or in the form of a cream applied into the vagina," says Ellen Marks.

This research is being done at MIVAC (the Mucosal Immunology and Vaccine Center) - the Sahlgrenska Academy's strategic research centre. Researchers at the centre are developing novel methods of treating diseases that affect our mucous membranes.

FACTS ABOUT CHLAMYDIA
The incidence of Chlamydia infection in Sweden has increased since the mid-nineties, especially in people under the age of 24. Last year, over 40 000 new cases were reported to the Swedish Institute for Infectious Disease Control. The disease is caused by the bacterium Chlamydia trachomatis, which is transmitted by unprotected sexual contact. Many don't realise that they have been infected, because Chlamydia infection often has no symptoms at all. Without effective antibiotic treatment the infection can become chronic and may even lead to infertility.
For further information, please contact:
Ellen Marks, tel. +46 (0)31-786 63 02 or +46 (0)73-710 46 24, ellen.marks@immuno.ge.se
Supervisor:-ma
Professor Nils Lycke, tel. +46 (0)31-786 63 21, nils.lycke@microbio.gu.se
Thesis for the degree of Doctor of Medical Science at the Department of Microbiology and Immunology, Institute of Biomedicine, the Sahlgrenska Academy.

Title of thesis: Genital tract CD4+ T cells for vaccination and protection against Chlamydia trachomatis

The thesis has been defended.

You can read the complete thesis here: http://hdl.handle.net/2077/21075

Helena Aaberg | idw
Further information:
http://hdl.handle.net/2077/21075
http://www.sahlgrenska.gu.se/english/

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>